Why Tevogen Bio Holdings Inc.’s (TVGN) Stock Is Down 7.04%
As of Monday, March 02, Tevogen Bio Holdings Inc.’s TVGN share price has dipped by 7.04%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.
Commentary & Analysis
Why Tevogen Bio Holdings Inc.’s (TVGN) Stock Is Down 5.67%
As of Friday, February 27, Tevogen Bio Holdings Inc.’s TVGN share price has dipped by 5.67%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Tevogen Bio Holdings Inc.’s (TVGN) Stock Is Down 5.45%
As of Friday, February 20, Tevogen Bio Holdings Inc.’s TVGN share price has dipped by 5.45%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Tevogen Bio Holdings Inc.’s (TVGN) Stock Is Up 6.02%
As of Thursday, February 19, Tevogen Bio Holdings Inc.’s TVGN share price has surged by 6.02%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Tevogen Bio Holdings Inc.’s (TVGN) Stock Is Up 6.31%
As of Friday, February 13, Tevogen Bio Holdings Inc.’s TVGN share price has surged by 6.31%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | TVGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $47.8 | $279.4 | 15% |
|
| Shares Out (Mil) | 3.8 | 54.3 | 12% |
|
| Institutional Ownership | 2.7% | 92.9% | 4% |
|
| Float (Mil) | 1.9 | 42.3 | 5% |
|
| Beta | 0.20 | 0.95 | 13% |
|
| Avg Daily Volume (000s) | 4 | 468 | 13% |
|
| Price Change (52-week) |
(83.3%) | 57.1% | 6% |
|
| Growth | TVGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.4% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TVGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($22) | ($43) | 23% |
|
| EPS (TTM) | ($6.321) | ($1.500) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($31) | 19% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $8 | $4 | 27% |
|
| Enterprise Value (Q1) (Mil) | $61 | $195 | 17% |
|
| Valuation | TVGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.74 | na |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | TVGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (73.5%) | na |
|
| ROA | (480.4%) | (47.8%) | 0% |
|
| ROE | 120.2% | (55.0%) | 97% |
|
| Liabilities to Assets | 288.0% | 29.8% | 99% |
|
| F-Score | 3 | 3 | 18% |
|
Tevogen Inc. did not pass any screens on 9/9/2026.
